Understanding the Vital Role of Genomic Testing in Lung Cancer Treatment — And Why Many Overlook Its Importance
Imagine a world where personalized medicine truly transforms cancer care, offering hope and tailored treatment plans based on a tumor's unique genetic makeup. But here's where it gets controversial: ensuring this precision approach is accessible and correctly implemented remains a significant challenge, especially in lung cancer. This is why it’s crucial for oncology nurses, advanced practitioners, and patient navigators to have a clear grasp of which biomarker tests are necessary for various lung cancer types, as these tests directly influence treatment decisions.
Recently, a dedicated session at the 16th Annual Academy of Oncology Nurse & Patient Navigators (AONN+) Conference held in New Orleans, Louisiana, shed light on the latest insights into genomic and genetic studies relevant to oncology navigation. The session notably included an in-depth presentation on genomic testing for non–small cell lung cancer (NSCLC), delivered by Jennifer Aversano, MSN, APRN, AGNP-C, OCN, ONN-CG. She is a seasoned lung oncology nurse navigator based at Endeavor Health-Northwest Community Hospital in Arlington Heights, Illinois.
The talk opened with a straightforward explanation of the difference between genetic and genomic investigations, especially pertinent for those new to the field. Aversano clarified that genetics involves studying genes and inheritance patterns, helping us understand how certain health conditions or traits pass from generation to generation through germline testing. This type of testing is primarily used in cancers like breast, ovarian, pancreatic, prostate, colorectal, endometrial, and gastric cancers.
On the other hand, genomics examines the comprehensive genetic profile of a tumor itself, focusing on somatic mutations that aren’t inherited but develop over time. Genomic analysis is particularly relevant for cancers such as lung, breast, colorectal, prostate, sarcoma, thyroid cancers, and metastatic melanoma, providing crucial insights into the tumor’s behavior and potential vulnerabilities.
Aversano then highlighted some sobering statistics related to lung cancer. Every year, approximately 2 million people in the United States are diagnosed with some form of cancer. Of these, about 11% are lung cancers. Projections for 2025 suggest that out of roughly 618,120 cancer-related deaths, over 124,700 will be attributable to lung cancer alone. This alarming data underscores that lung cancer remains the top cause of cancer death for both men and women in the U.S., surpassing the combined mortality from colon, breast, and prostate cancers in a single year.
Moving into practical applications, Aversano outlined the current landscape of molecular testing across different stages of NSCLC. For early-stage disease (Stage IA1-IA3), there are no specific testing recommendations at this time. However, once the cancer advances to Stage IB through IIIA and IIIB (T3-4, N2), the approach shifts:
- For tumors larger than 4 centimeters or those with lymph node involvement, testing is advised to inform neoadjuvant (pre-surgery) therapies.
- Key biomarkers to evaluate include PD-L1 expression, EGFR mutations, and ALK gene arrangements, as these determine targeted treatment options.
In cases of advanced or metastatic disease, the focus intensifies. Broad panel-based next-generation sequencing (NGS) and PD-L1 testing become essential—they help identify a variety of potential treatment pathways tailored to the specific molecular characteristics of the tumor. Ideally, a combination of assays should be used to detect emerging biomarkers, ensuring that no promising therapeutic target is missed.
Furthermore, Aversano referenced the National Comprehensive Cancer Network (NCCN) guidelines that outline comprehensive strategies for molecular and biomarker-driven therapies in patients with advanced or metastatic NSCLC. These guidelines serve as a critical resource for clinicians navigating the complexities of personalized treatment.
To make these concepts more tangible, she shared multiple case studies illustrating how different NSCLC types and their molecular profiles can influence treatment strategies—considering the patient’s disease stage, health history, and genetic testing results.
She wrapped up her presentation with an optimistic note: although lung cancer still holds the grim distinction of the highest mortality rate among all cancers, survival rates are gradually improving thanks to advances in molecular diagnostics and targeted therapies. Nevertheless, Aversano emphasized that molecular testing is especially vital for patients with stage IB and higher, as early identification of actionable mutations can significantly impact outcomes.
In conclusion, while we celebrate the progress made, it’s essential to question — are we doing enough to ensure all eligible lung cancer patients receive proper genomic testing? And how can healthcare professionals better advocate for widespread access to these advanced diagnostic tools? The ongoing debate about cost, accessibility, and implementation invites us to reflect: Are we truly leveraging the full potential of personalized medicine in fighting lung cancer?
